Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials (2006)

Peer-Reviewed Study · Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y · April 2006

Sakamoto J et al., 2006-04: Meta-analysis of three centrally randomised trials (1,094 patients) of PSK added to adjuvant chemotherapy after curative colorectal cancer resection: overall survival risk ratio 0.71 and disease-free survival 0.72.

The overall survival risk ratio for all eligible patients was 0.71 (95% confidence interval (CI) : 0.55-0.90; P=0.006), and the disease-free survival risk ratio was 0.72 (95% CI: 0.58-0.90; P=0.003).

Abstract

Sakamoto J et al., 2006-04: Meta-analysis of three centrally randomised trials (1,094 patients) of PSK added to adjuvant chemotherapy after curative colorectal cancer resection: overall survival risk ratio 0.71 and disease-free survival 0.72. Conducted by the Meta-Analysis Group of the Japanese Society for Cancer of the Colon and Rectum. Comparator: standard chemotherapy alone. Funding and per-author disclosures not carried in the PubMed record. Study type: review.